Decrease in urokinase-type plasminogen activator (u-PA) levels in patients with non-insulin dependent diabetes mellitus

Fibrinolysis and Proteolysis

Volumn 11, Issue 4, 1997, Pages 215-219

  Krekora, K ^a,b,c,d,e   Vitacolonna, E ^a   Di Castelnuovo, A ^a   D'Orazio, A ^a   De Lucia, D ^a   Dooijewaard, G ^a   Capani, F ^a   Donati, M B ^a   Lacoviello, L ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d TNO   (Netherlands)

^e Laboratorio Angela Valenti dei Fattori Genetici e Ambientali di Rischio Trombotico   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; HEMATOLOGICAL PARAMETERS; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SEX DIFFERENCE; VASCULAR DISEASE;

EID: 0030722940     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(97)80053-7     Document Type: Article

References (34)

1. Pan W H, Cèdres L B, Liu K, Dyer A, Schoenberger J A, Shekelle R B, Stamler R, Stamler J. Relationship of clinical diabetes and asymptomatic hyperglycemia to the risk of coronary-heart disease mortality in men and women. Am J Epidemiol 1986; 123: 504-516.
2. Bierman E L. Atherogenesis in diabetes. Arterioscler Thromb 1992; 12: 647-656.
3. Kännel W B, D'Agostino R B, Wilson P W, Belanger A J, Gagnon D R. Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. Am Heart J 1990; 120: 672-676.
4. Fontbonne A. Why can high insulin levels indicate a risk for coronary heart disease? Diabetologia 1994; 37: 953-955.
5. Juhan-Vague I, Roul C, Alessi M C, Heim M, Vague P. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients - relationship with plasma insulin. Thromb Haemost 1989; 61: 370-373.
6. Ostermann H, van de Loo. Factors of the hemostatic system in diabetic patients. A survey of controlled studies. Haemostasis 1986; 16:386-416.
7. Dooijewaard G, de Boer A, Turion P, Cohen A F, Breimer D D, Kluft C. Physical exercise induces enhancement of urokinasetype plasminogen activator (u-PA) levels in plasma. Thromb Haemost 1991; 65: 82-86.
8. Imura Y, Stassen J M, Kurokawa T, Iwasa S, Lijnen H R, Collen D. Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons. Blood 1992; 79: 2322-2329.
9. Van De Werf F, Nobuhara M, Collen D. Coronary thrombolysis with human single-chain, urokinase-type plasminogen activator (pro-urokinase) in patients with acute myocardial infarction. Ann Intern Med 1986; 104: 345-348.
10. Wun T C, Schleuning W D, Reich E. Isolation and characterization of urokinase from human plasma. J Biol Chem 1982; 257: 3276-3283.
11. Gurewich V, Pannell R, Lovie S. Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase) - a study in vitro and in vivo in two animal species. J Clin Invest 1984; 73: 1731-1739.
12. Binnema D, Dooijewaard G, Turion P. An analysis of the activators of single-chain urokinase-type plasminogen activator (scu-PA) in the dextran sulphate euglobulin fraction of normal plasma and of plasma deficient in factor XII and prekallikrein. Thromb Haemost 1991; 65: 144-148.
13. WojtaJ, Hoover R L, Daniel T O. Vascular origin determines plasminogen activator expression in human endothelial cells. Renal endothelial cells produce large amounts of single chain urokinase type plasminogen activator. J Biol Chem 1989; 264: 2846-2851.
14. Pepper M S, Vassalli J D, Montesano R, Orci L. Urokinase-type plasminogen activator is induced in migrating capillary endothelial cells. J Cell Biol 1987; 105:2535-2541.
15. Ny T, Bjersing L, Hsueh A J W, Loskutoff D J. Cultured granulosa cells produce two plasminogen activators and an antiactivator, each regulated differently by gonadotropins. Endocrinology 1985; 116: 1666-1668.
16. Dano K, Andreasen P A, Grondahl-Hansen J, Kristensen P, Nielsen L S, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985; 44: 139-266.
17. Krystosek A, Seeds N W. Plasminogen activator release at the neuronal growth cone. Science 1981; 213: 1532-1534.
18. Liotta L A, Steeg P S, Stetler-Stevenson W G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991; 64: 327-336.
19. Ossowski L, Biegel D, Reich E. Mammary plasminogen activator: correlation with involution, hormonal modulation and comparison between normal and neoplastic tissue. Cell 1979; 16: 929-940.
20. Carmeliet P, Collen D. Evaluation of the plasminogen/plasmin system in transgenic mice. Fibrinolysis 1994; 8 (Supp 1): 269-276.
21. de Gaetano G, Carriero M R, Cerletti C, Mussoni L. Low dose aspirin does not prevent fibrinolytic response to venous occlusion. Biochem Pharmacol 1986; 35: 3147-3150.
22. Clauss A. Gerinnungsphysiologische schnellmethode zur bestimmung des fibrinogens. Acta Haematol 1957; 17: 237-246.
23. Bergsdorf N, Nilsson T, Wallen P. An enzyme linked immunoabsorbent assay for determination of tissue plasminogen activator applied to patients with thromboembolic disease. Thromb Haemost 1983; 50: 740-744.
24. Declerck P J, Alessi M C, Verstreken M, Kruithof E K O, JuhanVague I, Collen D. Measurement of plasminogen activator inhibitor l (PA1-1) in biological fluids, with a murine monoclonal antibody based enzyme-linked immunosorbent assay. Blood 1988; 71: 220-225.
25. Binnema D, Van lersel J J L, Dooijewaard G. Quantitation of urokinase antigen in plasma and culture media by use of an ELISA. Thromb Res 1986; 43: 569-577.
26. van Hinsberg V W M, Berd E A vd, Fiers W, Dooijewaard G. Tumor necrosis factor induces the production of urokinasetype plasminogen activator by human endothelial cells. Blood 1990; 75: 1991-1998.
27. Ridker P M. Vaughan D E, Stampfer M J, Manson J E, Hennekens C H. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341: 1165-1168.
28. ECAT Angina Pectoris Study Group. ECAT angina pectoris study: baseline association of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Europ Heart] 1993; 14: 8-17.
29. AuwerxJ, Bouillon R, Collen D, GeboersJ. Tissue-type activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 1988; 8: 68-72.
30. Pandolfi A, lacoviello L, Capani F, Vitacolonna E, Donati M B, Consoli A. Glucose and insulin independently reduce the fibrinolytic potential of human vascular smooth muscle cells in culture. Diabetologia 1996; 39: 1425-1431.
31. Nicoloso G, Havert J, Kruithof E K O, Meile G V, Bachmann F. Fibrinolysis in normal subjects: comparison between plasminogen activator inhibitor and other components of the fibrinolytic system. Thromb Haemost 1988; 59: 299-303.
32. Darras V, Thienpont M, Stump D C, Collen D. Measurement of urokinase-type plasminogen activator inhibitor (uPA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies. Thromb Haemost 1986; 56: 411-414.
33. Falkon L, Gari' M, Barrel M, Fontcuberta L. The release of plasminogen activators (tPA and uPA) and plasminogen activator inhibitor (PAI-1) after venous stasis. Blood Coag Fib 1992; 3:33-38.
34. Al-Roof Higazi B A, Mazar A, WangJ, Reilly R, Henkin J, Kniss D, Cinés D. Single-chain urokinase-type plasminogen activator bound to its receptor is relatively resistant to plasminogen activator inhibitor type-1. Blood 1996; 87: 3545-3549.